electroCore, Inc. Announces Study of gammaCore Sapphire™ for the Treatment of Post-COVID Syndrome
07 juil. 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., July 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced Mayo Clinic is initiating an...
electroCore Announces Listing Transfer to the Nasdaq Capital Market
23 juin 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., June 23, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has received approval...
electroCore, Inc. Announces gammaCore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers
24 mai 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., May 24, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the gammaCore Sapphire™ non-invasive vagus...
electroCore to Participate at Upcoming Investor Conferences
18 mai 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan...
electroCore Announces Record First Quarter 2022 Financial Results
05 mai 2022 16h00 HE
|
electroCore, Inc.
First quarter 2022 net sales of $1.9 million, approximately 58% over first quarter 2021 and 27% sequentially Company to host a conference call and webcast today, May 5, 2022 at, 4:30 PM EDT ...
electroCore to Announce First Quarter 2022 Financial Results on May 5
28 avr. 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the...
electroCore Completes Sale of New Jersey Tax Benefits
26 avr. 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has completed the sale of its...
electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers in Neurology
21 avr. 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., April 21, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Frontiers in Neurology has published...
gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) Selected for Department of Defense Biotech Optimized for Operational Solutions and Tactics (BOOST) Program
19 avr. 2022 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore™ nVNS has been selected for...
electroCore Provides Business Update and Select First Quarter 2022 Financial Guidance
12 avr. 2022 08h00 HE
|
electroCore, Inc.
Record revenue from product sales will be approximately $1.9M; approximately 60% growth over first quarter 2021March 31, 2022, cash balance of approximately $29.9M ROCKAWAY, N.J., April 12, 2022 ...